(Q35048301)

English

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study (English)

1 reference

Europe PubMed Central

6 August 2017

0 references

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Kazuyoshi Saito

11

object named as

Kazuyoshi Saito

1 reference

Europe PubMed Central

6 August 2017

author name string

Yoshiya Tanaka

1

1 reference

Europe PubMed Central

6 August 2017

Shintaro Hirata

2

1 reference

Europe PubMed Central

6 August 2017

Satoshi Kubo

3

1 reference

Europe PubMed Central

6 August 2017

Shunsuke Fukuyo

4

1 reference

Europe PubMed Central

6 August 2017

Kentaro Hanami

5

1 reference

Europe PubMed Central

6 August 2017

Norifumi Sawamukai

6

1 reference

Europe PubMed Central

6 August 2017

Kazuhisa Nakano

7

1 reference

Europe PubMed Central

6 August 2017

Shingo Nakayamada

8

1 reference

Europe PubMed Central

6 August 2017

Kunihiro Yamaoka

9

1 reference

Europe PubMed Central

6 August 2017

Fusae Sawamura

10

1 reference

Europe PubMed Central

6 August 2017

language of work or name

0 references

publication date

28 November 2013

1 reference

Europe PubMed Central

6 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

6 August 2017

74

1 reference

Europe PubMed Central

6 August 2017

389-395

1 reference

Europe PubMed Central

6 August 2017

2

1 reference

Europe PubMed Central

6 August 2017

Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316845

8 July 2018

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316845

8 July 2018

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316845

8 July 2018

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316845

8 July 2018

Differences in binding and effector functions between classes of TNF antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316845

8 July 2018

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316845

8 July 2018

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316845

8 July 2018

Apoptosis as a therapeutic tool in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316845

8 July 2018

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316845

8 July 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316845

8 July 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316845

8 July 2018

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204016

21 January 2018

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204016

21 January 2018

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204016

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204016

21 January 2018

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316845

25 October 2018

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316845

9 December 2018

How to read radiographs according to the Sharp/van der Heijde method

1 reference

https://pubmed.ncbi.nlm.nih.gov/24288014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24288014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/24288014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24288014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24288014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2013-204016

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35048301&oldid=2087541762"